Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL.
about
The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy.Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation.Minimal residual disease surveillance in chronic lymphocytic leukemia by fluorescence-activated cell sorting.Technical issues: flow cytometry and rare event analysis.Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia.Prognostic signature and clonality pattern of recurrently mutated genes in inactive chronic lymphocytic leukemiaMinimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study.Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia.Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia.Role of high expression of IL-9 in prognosis of CLL.Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia.[Leukemia research in Germany: the Competence Network Acute and Chronic Leukemias].Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry.Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting.Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemia.Morphology and immunophenotyping issues in the integrated diagnosis of hematologic disorders of elderly patients.Comparison of two real-time quantitative polymerase chain reaction strategies for minimal residual disease evaluation in lymphoproliferative disorders: correlation between immunoglobulin gene mutation load and real-time quantitative polymerase chainDetecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice.ROR1-based immunomagnetic protocol allows efficient separation of CLL and healthy B cells.Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.Improved survival outcomes with the addition of rituximab to initial therapy for chronic lymphocytic leukemia: a comparative effectiveness analysis in the province of British Columbia, Canada.Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project.Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL.Tandem dyes: Stability in cocktails and compensation considerations.Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry.Minimal residual disease detected by immunoglobulin sequencing predicts CLL relapse more effectively than flow cytometry.Novel lymphocyte screening tube using dried monoclonal antibody reagents.The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia.Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR.Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase II study.Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia.Detection of minimal residual disease in mantle cell lymphoma-establishment of novel eight-color flow cytometry approach.[Chronic lymphocytic leukemia : treatment concepts in transition].
P2860
Q33558740-4186E725-DD3E-488C-AE79-B565C140119CQ33794311-A229B9B6-5BF4-46DF-BDF6-A40B15FCE62FQ34380489-5EED08D3-0CC6-479D-9CE6-E9679B993E99Q34463414-6E982FF1-B822-49B6-A77A-E0C27F46089DQ34670653-1712CD35-A3A7-47F4-B7D8-36F8246931FCQ35040222-FA458FFE-C19B-4BA6-B29D-45B1435DDFD0Q36022532-DDCE8F92-FB24-4412-8598-968111EE7672Q36750463-DC22A643-A38F-4C96-9E07-2382F6E65F46Q36788133-6A3919D2-BE48-44C9-A725-D0BBBB6F90DCQ36799192-6D423FCA-D637-4244-BBE4-1FB1B5C33B55Q37087424-05D27EB1-7A77-4124-B268-04B5E1B93FC0Q37429218-80F02E9C-F503-43C8-8959-744B3199E447Q37587401-91F39E14-766F-4DC8-A313-1F6AD86D1B3AQ37710733-66AA15E2-A964-4929-9233-81DF1390916CQ38382105-1CE57F24-BCA2-4F8C-AD31-9626E547A00AQ38438814-CDEA75FB-7E49-41AA-A46C-E7C299A3BCD5Q39050210-1CB121D8-D5F1-4B70-9787-084F88676C10Q40397638-D49EAF04-45AF-46C2-B330-6C5D5FA85C16Q41125227-407EC9A0-2062-4756-9C53-09A5727937CEQ42609619-F6C76B05-411B-4901-866D-21010AB2573DQ44006669-D7DC0E57-D062-4C4B-9C1F-DCCF538F852EQ45110231-C31FC48E-C3C2-4C58-83AB-1B754B1E6EECQ45880689-063BBA7F-1354-41D0-A389-7D080BD33ABAQ47300370-390F1F25-D4F8-4057-B016-240D621B1FA1Q47664480-B97CF490-8DBF-4577-9169-3135293E7EADQ47793348-2C81963F-CD62-4DC3-A77D-0BF85339F3DAQ48198290-003DD3E6-0D61-4732-A635-10B037DD3AD2Q48367614-C4C7C225-8FB7-4559-B080-DC8E3CFD6A9DQ48897298-D4741738-916F-4CDC-B985-8353AFAC1AA4Q49641900-ACA2E8B2-07F4-4358-9F96-6BCC005C688DQ49818588-7BB5412F-D6D0-408D-9DC9-821CD0DC22B4Q50446308-D9310564-6F59-4FF1-90FA-31A2A8C56914Q51014811-0365B546-BC43-4D50-BFA2-FE6E0875ED84Q51741519-A6CDC454-2A9B-4AE7-A797-CD31B0AAFACFQ52684522-8AF1C6B4-4090-4F2C-A6B1-ED900DF013E6Q52770382-EDA93B4F-DDFE-4C1A-960B-E62A44F69C7EQ54177481-EA77993D-F686-45F6-9623-B9B41105A385Q55064971-82CB9E7B-5764-4CE3-A491-67C69C9E36DD
P2860
Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Improving efficiency and sensi ...... ual disease monitoring in CLL.
@en
Improving efficiency and sensi ...... ual disease monitoring in CLL.
@en-gb
Improving efficiency and sensitivity: European Research Initiative in CLL
@nl
type
label
Improving efficiency and sensi ...... ual disease monitoring in CLL.
@en
Improving efficiency and sensi ...... ual disease monitoring in CLL.
@en-gb
Improving efficiency and sensitivity: European Research Initiative in CLL
@nl
prefLabel
Improving efficiency and sensi ...... ual disease monitoring in CLL.
@en
Improving efficiency and sensi ...... ual disease monitoring in CLL.
@en-gb
Improving efficiency and sensitivity: European Research Initiative in CLL
@nl
P2093
P2860
P50
P356
P1433
P1476
Improving efficiency and sensi ...... ual disease monitoring in CLL.
@en
P2093
A R Pettitt
E Montserrat
European Research Initiative in CLL
F Cymbalista
H Kartsios
J Shingles
P2860
P2888
P304
P356
10.1038/LEU.2012.216
P577
2012-07-31T00:00:00Z
P5875
P6179
1052508507